These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 1375948

  • 21. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 22. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 23. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
    Rooke R, Tremblay M, Wainberg MA.
    Virology; 1990 May 18; 176(1):205-15. PubMed ID: 1691885
    [Abstract] [Full Text] [Related]

  • 24. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Reid P, MacInnes H, Cong ME, Heneine W, García-Lerma JG.
    Virology; 2005 Jun 05; 336(2):251-64. PubMed ID: 15892966
    [Abstract] [Full Text] [Related]

  • 25. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
    Kellam P, Boucher CA, Tijnagel JM, Larder BA.
    J Gen Virol; 1994 Feb 05; 75 ( Pt 2)():341-51. PubMed ID: 7509370
    [Abstract] [Full Text] [Related]

  • 26. Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy.
    Kondo M.
    Kansenshogaku Zasshi; 1995 Nov 05; 69(11):1278-85. PubMed ID: 8708409
    [Abstract] [Full Text] [Related]

  • 27. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE, Franco S, Martínez MA, Menéndez-Arias L.
    J Mol Biol; 2007 Jan 12; 365(2):298-309. PubMed ID: 17070543
    [Abstract] [Full Text] [Related]

  • 28. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY, Vrang L, Oberg B, Merigan TC.
    AIDS Res Hum Retroviruses; 2001 Mar 20; 17(5):401-7. PubMed ID: 11282008
    [Abstract] [Full Text] [Related]

  • 29. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL, Das K, Arnold E, Hughes SH.
    Antimicrob Agents Chemother; 2015 Dec 20; 59(12):7184-96. PubMed ID: 26324274
    [Abstract] [Full Text] [Related]

  • 30. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH.
    J Virol; 2004 Sep 20; 78(18):9987-97. PubMed ID: 15331732
    [Abstract] [Full Text] [Related]

  • 31. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW.
    J Virol; 2007 Aug 20; 81(15):7852-9. PubMed ID: 17507476
    [Abstract] [Full Text] [Related]

  • 32. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.
    Mas A, Parera M, Briones C, Soriano V, Martínez MA, Domingo E, Menéndez-Arias L.
    EMBO J; 2000 Nov 01; 19(21):5752-61. PubMed ID: 11060026
    [Abstract] [Full Text] [Related]

  • 33. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.
    Virology; 2001 May 10; 283(2):294-305. PubMed ID: 11336554
    [Abstract] [Full Text] [Related]

  • 34. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
    Qari SH, Winters M, Vandamme AM, Merigan T, Heneine W.
    Antivir Ther; 2002 Jun 10; 7(2):131-9. PubMed ID: 12212925
    [Abstract] [Full Text] [Related]

  • 35. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 10; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 36. [Investigation of AZT sensitivity of HIV-1 isolates from patients treated with AZT].
    Saito T, Kondo M, Ito A, Nagao T, Imai M.
    Kansenshogaku Zasshi; 1993 Apr 10; 67(4):311-4. PubMed ID: 8315299
    [Abstract] [Full Text] [Related]

  • 37. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
    Boyer PL, Sarafianos SG, Arnold E, Hughes SH.
    J Virol; 2001 May 10; 75(10):4832-42. PubMed ID: 11312355
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
    Kaye S, Comber E, Tenant-Flowers M, Loveday C.
    AIDS Res Hum Retroviruses; 1995 Oct 10; 11(10):1221-5. PubMed ID: 8573378
    [Abstract] [Full Text] [Related]

  • 40. AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase.
    Schneider A, Schweimer K, Rösch P, Wöhrl BM.
    Retrovirology; 2015 Feb 22; 12():21. PubMed ID: 25808094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.